Jonathan M. Brotchie
Affiliations: | Toronto Western Research Institute, Toronto, Ontario, Canada |
Area:
neurodegenerative disordersGoogle:
"Jonathan Brotchie"Mean distance: 16.93 (cluster 6)
Children
Sign in to add trainee| Timothy M. Brown | grad student | The University of Manchester | |
| Erwan Bezard | post-doc | 1999-2000 | The University of Manchester |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Musacchio T, Yin J, Kremer F, et al. (2022) Temporal, spatial and molecular pattern of dopaminergic neurodegeneration in the AAV-A53T α-synuclein rat model of Parkinson's disease. Behavioural Brain Research. 432: 113968 |
| Hauser RA, Giladi N, Poewe W, et al. (2022) P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease. Advances in Therapy. 39: 1881-1894 |
| Schneider JS, Marshall CA, Keibel L, et al. (2020) A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease. Experimental Neurology. 335: 113514 |
| Depoortere R, Johnston TH, Fox SH, et al. (2020) The selective 5-HT receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques. Parkinsonism & Related Disorders. 78: 151-157 |
| Titze-de-Almeida SS, Soto-Sánchez C, Fernandez E, et al. (2020) The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's Disease. Cells. 9 |
| McKinnon C, De Snoo ML, Gondard E, et al. (2020) Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein. Acta Neuropathologica Communications. 8: 17 |
| Barth AL, Schneider JS, Johnston TH, et al. (2020) NYX-458 improves cognitive performance in a primate Parkinson's disease model. Movement Disorders : Official Journal of the Movement Disorder Society |
| Schneider JS, Aras R, Williams CK, et al. (2019) GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson's Disease. Scientific Reports. 9: 8362 |
| Howson PA, Johnston TH, Ravenscroft P, et al. (2019) Beneficial effects of trehalose on striatal dopaminergic deficits in rodent and primate models of synucleinopathy in Parkinson's disease. The Journal of Pharmacology and Experimental Therapeutics |
| Johnston TH, Geva M, Steiner L, et al. (2018) Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques. Movement Disorders : Official Journal of the Movement Disorder Society |